Results 31 to 40 of about 3,904 (178)
Risankizumab: Daily Practice Experience of High Need Patients [PDF]
, 2023 Psoriasis is a chronic inflammatory disease which affects 29.5 million people worldwide and it can negatively impact quality of life, especially when it affects a special localization, such as nails, face, palms and soles, or intertriginous regions ...
Caldarola G.
core +3 more sources
Peristomal Pyoderma Gangrenosum Responding to Risankizumab [PDF]
, 2021 Evidence to support available therapies for pyoderma gangrenosum (PG) is limited. Many patients do not respond to topical therapies such as tacrolimus or topical steroids. Currently favored oral systemic treatments (eg, cyclosporine and steroids) achieve
Kirsner, Robert S +1 more
core +1 more source
Global & Regional Health Technology Assessment, 2021 Purpose: The objective of this analysis was to compare the cost per responder between risankizumab and secukinumab among patients with moderate-to-severe plaque psoriasis in Italy.
Paolo Gisondi +3 more
doaj +1 more source
Efficacy and safety of treatment of moderate and severe psoriasis with the interleukin 23 inhibitor risankizumab [PDF]
Vestnik Dermatologii i Venerologii, 2022 A review of the literature on the use of the genetically engineered biological drug Skyrizi (INN: risankizumab) for the treatment of psoriasis in patients is presented. The problem of high dissatisfaction of patients with the available means (methods) of
Andrey L. Bakulev, Larisa S. Kruglova
doaj +1 more source
Frontiers in Immunology, 2023 BackgroundRisankizumab, a humanized IgG1 monoclonal antibody that selectively inhibits IL-23, is currently approved for the treatment of moderate-to-severe plaque psoriasis and Crohn’s disease.
Yamin Shu +3 more
doaj +1 more source
Risankizumab in the treatment of psoriasis – literature review
Rheumatology, 2019 Risankizumab is a humanized, monoclonal antibody directed against subunit p19 of interleukin 23 (IL-23). In February 2019, risankizumab was approved for the treatment of moderate to severe psoriasis.
Katarzyna Banaszczyk
doaj +1 more source
A non-clinical comparative study of IL-23 antibodies in psoriasis
mAbs, 2021 Four antibodies that inhibit interleukin (IL)-23 are approved for the treatment of moderate-to-severe plaque psoriasis. Here, we present non-clinical data comparing ustekinumab, guselkumab, tildrakizumab and risankizumab with regard to thermostability ...
Li Zhou +19 more
doaj +1 more source
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial [PDF]
, 2023 225231OBJECTIVE: To evaluate risankizumab, a biological therapy that inhibits interleukin 23, in patients with active psoriatic arthritis (PsA) who have responded inadequately or are intolerant to ≥1 conventional synthetic disease-modifying antirheumatic
Papp, K. +10 more
core +1 more source
Risankizumab i behandlingen av moderat til alvorlig psoriasis hos voksne [PDF]
, 2022 Background: Psoriasis is a common chronic inflammatory skin disease with a considerable impact on quality of life. With their specificity and efficacy biologics are improving the outcome for patients with psoriasis in an outstanding manner.
Nilsen, Erik
core
Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis [PDF]
, 2020 Objective: Risankizumab (Skyrizi), an interleukin-23 (IL-23) antagonist, was approved by the Food and Drug Administration (FDA) for the treatment of moderate to severe plaque psoriasis in April 2019.
Haidari, Wasim +3 more
core +1 more source